Scott Biller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics

Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPat sharpVineeta agarwalaBen horowitzJordi mata finkScott billerAndreessen horowitzJames winklerBrian cathersClare ozawaEtom danielRaman talwarAjay parrishMarc andreessenEarly development at celgeneGlobal research

Novel drug-discovery approach lands big backers

UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases.

Scott billerRos deeganDame carol robinsonDiana bernsteinShouti pharmaceuticalsOxford science enterprisesOxford universityUnited kingdom basedSanofi venturesNorthpond venturesGoogle venturesLaia crespoJeantet prizeFranklin medalWeight lossMedical devices

OMass Therapeutics Raises $100 Million in Series B

PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new.

United statesNew yorkUnited kingdomMountain viewCity ofSan franciscoScott billerRos deeganEdward hodgkinDame carol robinsonDiana bernsteinRosamond deeganOmass odyssSilicon valley bankOxford science enterprisesFlatiron health

OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesNew yorkUnited kingdomMountain viewCity ofSan franciscoScott billerRos deeganEdward hodgkinDame carol robinsonDiana bernsteinRosamond deeganOmass odyssSilicon valley bankOxford science enterprisesFlatiron health

Sanofi-Backed OMass Therapeutics Rakes in $100M to Drug the Undruggable

Oxford, UK-based OMass Therapeutics closed on a $100 million Series B financing round. The round was led by new investors GV (formerly Google Ventures), Northpond Ventures and Sanofi Ventures. Three existing investors also participated: Syncona, Oxford Science Enterprise and Oxford University.

United kingdomScott billerOmass therapeuticsclosedChas bountraDame carol robinsonJohn yatesDiana bernsteinJames naismithRos deeganErnestw hahnFiona marshallRosalind franklin instituteOxford sciences innovationCentre for medicines discoveryUniversity of oxfordMerck co